FRLNFreeline Therapeutics Holdi...

Nasdaq www.freeline.life


$ 6.43 $ 0.00 (0 %)    

Monday, 12-Feb-2024 15:35:34 EST
QQQ $ 433.62 $ 1.37 (0.32 %)
DIA $ 385.74 $ -1.02 (-0.26 %)
SPY $ 509.34 $ -1.20 (-0.24 %)
TLT $ 89.58 $ -0.53 (-0.59 %)
GLD $ 212.33 $ -1.09 (-0.51 %)
$ 6.48
$ 6.46
$ 0.00 x 0
$ 6.49 x 100
$ 6.43 - $ 6.46
$ 2.11 - $ 8.74
5,663
na
25.61M
$ 1.47
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-downgrades-freeline-therapeutics-to-neutral-lowers-price-target-to-65

HC Wainwright & Co. analyst Patrick Trucchio downgrades Freeline Therapeutics (NASDAQ:FRLN) from Buy to Neutral and lowe...

 gene-therapy-player-freeline-therapeutics-goes-private-in-28m-deal

London-listed Syncona Ltd has agreed to acquire Freeline Therapeutics Holdings plc (NASDAQ: FRLN) in an all-cash transaction fo...

 why-nuvve-holding-shares-are-trading-lower-by-45-here-are-other-stocks-moving-in-wednesdays-mid-day-session

Gainers Shift Technologies, Inc. (NASDAQ: SFT) shares climbed 107.8% to $0.2239. Shift Technologies recently said it will f...

 wedbush-downgrades-freeline-therapeutics-to-neutral-lowers-price-target-to-5

Wedbush analyst David Nierengarten downgrades Freeline Therapeutics (NASDAQ:FRLN) from Outperform to Neutral and lowers the ...

 why-is-gene-therapy-player-freeline-therapeutics-stock-trading-higher-today

Freeline Therapeutics Holdings plc (NASDAQ: FRLN) reported initial data from the ongoing Phase 1/2 GALILEO-1 trial of FLT201, i...

Core News & Articles

FRLN: 88% | Freeline Reports Positive Initial Clinical Data from First Cohort of Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel...

 freeline-therapeutics-shares-are-trading-higher-after-the-company-released-initial-data-from-first-cohort-of-phase-12-galileo-1-trial-of-flt201-gene-therapy-for-gaucher-disease

Freeline Reports Positive Initial Clinical Data fromFreeline Reports Positive Initial Clinical Data from

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION